Ceribell vs VUNO (2026)
Two acute risk algorithms with opposite hardware answers, which is the useful thing about putting them side by side. Ceribell brings its own instrument: a rapidly placed headband feeding a machine learning model that estimates seizure burden and alerts clinicians to suspected status epilepticus, in departments where no neurologist is standing by. VUNO brings nothing at all, predicting in hospital cardiac arrest within a day from four vital signs the ward already charts, with independent multicentre validation across several tertiary hospitals. Neither competes with the other clinically. What they illustrate together is the trade every acute prediction buyer makes: a device gives you a signal nobody currently collects and a cost per patient, while a model over existing data is free of consumables and limited to what the chart already knows.
- The hardware exists to serve the algorithm rather than the other way round, letting a non specialist place a headband and get an interpreted result where a conventional study needs a technologist and a neurologist.
- A clear regulatory leader in its niche with a progression of clearances including age specific expansions, which functions as de facto evidence that performance was examined per population.
- The algorithm's operation is described with unusual specificity, interpreting continuously across channels to produce a burden estimate rather than a single classification.
- It uses only four routinely charted vital signs, so there is no device to buy, no consumable and no new workflow, and the model consumes what the record already contains.
- The evidence is genuinely independent and multicentre across several tertiary hospitals, which addresses site level generalisability better than most deterioration models in this index.
- Inputs and outputs are stated precisely, four named vital signs producing a bounded score over a defined horizon, so a clinical team knows exactly what the number means.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Ceribell and VUNO are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Ceribell | VUNO |
|---|---|---|
| Primary category | Diagnostics & Genomics | Clinical Decision Support |
| Founded | 2014 | 2014 |
| Headquarters | Sunnyvale, California, United States | Seoul, South Korea |
| Website | ceribell.com | vuno.co |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Ceribell its top capability grade on AI Centrality and FDA and Regulatory Status. Set against VUNO, Ceribell grades higher on Security Certifications and Trust Center, FDA and Regulatory Status and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards VUNO its top capability grade on AI Centrality and Clinical and Operational Evidence. Set against Ceribell, VUNO grades higher on Clinical and Operational Evidence and EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Ceribell or VUNO?
On the axes where the AI Health Index separates them, Ceribell grades higher on Security Certifications and Trust Center, FDA and Regulatory Status and Setting and Specialty Coverage, and VUNO grades higher on Clinical and Operational Evidence and EHR and Interoperability Depth. Ceribell leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Ceribell and VUNO differ most?
The widest separation the AI Health Index records between Ceribell and VUNO is on Security Certifications and Trust Center, where Ceribell grades B and VUNO grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Ceribell and VUNO grade the same?
The AI Health Index grades Ceribell and VUNO the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Ceribell and VUNO not disclosed?
At the last review, at least one of Ceribell and VUNO published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These products address different clinical questions, seizure detection at the point of care and cardiac arrest prediction on the ward, and are compared here because both are algorithm led acute risk products, not because a hospital would choose between them. Regulatory status differs by product and jurisdiction for both vendors and should be checked per product rather than per company. Neither publishes a business associate posture, and neither publishes hosting or residency detail. VUNO's validation is Korean, so a United States buyer should ask what performance looks like in a population with different baseline vital sign distributions and different escalation practices.